Schrum Private Wealth Management LLC Sells 331 Shares of Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Apr 1st, 2023

Schrum Private Wealth Management LLC lessened its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 4.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,222 shares of the company’s stock after selling 331 shares during the period. Johnson & Johnson makes up about 1.5% of Schrum Private Wealth Management LLC’s investment portfolio, making the stock its 21st largest holding. Schrum Private Wealth Management LLC’s holdings in Johnson & Johnson were worth $1,276,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in JNJ. Lincoln Capital Corp lifted its position in Johnson & Johnson by 15.9% during the third quarter. Lincoln Capital Corp now owns 1,332 shares of the company’s stock valued at $218,000 after purchasing an additional 183 shares in the last quarter. Ieq Capital LLC lifted its position in shares of Johnson & Johnson by 5.1% in the third quarter. Ieq Capital LLC now owns 128,012 shares of the company’s stock worth $20,912,000 after buying an additional 6,154 shares in the last quarter. RFG Advisory LLC increased its stake in Johnson & Johnson by 2.7% during the third quarter. RFG Advisory LLC now owns 22,434 shares of the company’s stock worth $3,900,000 after acquiring an additional 594 shares during the last quarter. Willis Investment Counsel increased its stake in Johnson & Johnson by 0.4% during the fourth quarter. Willis Investment Counsel now owns 328,884 shares of the company’s stock worth $58,097,000 after acquiring an additional 1,358 shares during the last quarter. Finally, FDx Advisors Inc. increased its stake in Johnson & Johnson by 0.3% during the third quarter. FDx Advisors Inc. now owns 50,421 shares of the company’s stock worth $8,237,000 after acquiring an additional 153 shares during the last quarter. Institutional investors own 67.94% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $155.00 on Friday. The company has a fifty day simple moving average of $158.02 and a two-hundred day simple moving average of $167.12. The company has a market cap of $403.66 billion, a price-to-earnings ratio of 23.00, a price-to-earnings-growth ratio of 2.64 and a beta of 0.54. The company has a quick ratio of 0.77, a current ratio of 0.99 and a debt-to-equity ratio of 0.35. Johnson & Johnson has a 52 week low of $150.11 and a 52 week high of $186.69.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings data on Tuesday, January 24th. The company reported $2.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.22 by $0.13. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. The business had revenue of $23.71 billion during the quarter, compared to analysts’ expectations of $23.90 billion. During the same period in the previous year, the company earned $2.13 EPS. The company’s revenue for the quarter was down 4.4% on a year-over-year basis. As a group, equities analysts anticipate that Johnson & Johnson will post 10.5 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st were issued a $1.13 dividend. The ex-dividend date of this dividend was Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.92%. Johnson & Johnson’s payout ratio is 67.06%.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Wednesday, February 1st. UBS Group initiated coverage on Johnson & Johnson in a report on Tuesday. They set a “neutral” rating and a $164.00 price objective for the company. Atlantic Securities upped their target price on Johnson & Johnson from $160.00 to $168.00 and gave the company a “neutral” rating in a research report on Wednesday, January 25th. Guggenheim initiated coverage on Johnson & Johnson in a research report on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 target price on the stock. Finally, SVB Leerink cut their target price on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research report on Friday, January 20th. Eight equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $173.67.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the transaction, the insider now directly owns 9,215 shares in the company, valued at $1,425,191.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.35% of the company’s stock.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.